Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company’s oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005.[1]

In February 2018, Merck & Co. announced it would acquire Viralytics for AUD$502 million ($394 million).[2]


The trial, published today in Clinical Cancer Research and led by researchers at the University of Surrey, U.K., involved fifteen patients who were treated with a virus called CVA21, a naturally occurring virus which causes the common cold, with some impressive results.

Det håpløse viruset som Viralytics utviklet, cavatc, ga lovende data i blærekreft-pasienter.

1 Like